Intercorrelation of Molecular Biomarkers and Clinical Phenotype Measures in Fragile X Syndrome
Cells · 2023
DOI: 10.3390/cells12141920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Ramkumar Aishworiya und 17 weiteren Autor:innen. Beteiligte Einrichtung: MIND Institute, University of California Davis Medical Center, Sacramento, CA 95817, USA. Hauptthemen laut MEDLINE: Fragile X Syndrome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, Azrieli Foundation, MIND Institute IDDRC.
Abstract (Originalsprache)
This study contributes to a greater understanding of the utility of molecular biomarkers to identify clinical phenotypes of fragile X syndrome (FXS). Correlations of baseline clinical trial data (molecular measures—FMR1 mRNA, CYFIP1 mRNA, MMP9 and FMRP protein expression levels, nonverbal IQ, body mass index and weight, language level, NIH Toolbox, adaptive behavior rating, autism, and other mental health correlates) of 59 participants with FXS ages of 6–32 years are reported. FMR1 mRNA expression levels correlated positively with adaptive functioning levels, expressive language, and specific NIH Toolbox measures. The findings of a positive correlation of MMP-9 levels with obesity, CYFIP1 mRNA with mood and autistic symptoms, and FMR1 mRNA expression level with better cognitive, language, and adaptive functions indicate potential biomarkers for specific FXS phenotypes. These may be potential markers for future clinical trials for targeted treatments of FXS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MIND Institute, University of California Davis Medical Center, Sacramento, CA 95817, USA.
- Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore 119074, Singapore.
- Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore.
- Department of Psychiatry, National Cheng Kung University Hospital, Tainan 704, Taiwan.
- Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
- Department of Public Health Sciences, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
ORCID-Profile: Ramkumar Aishworiya, Marwa Zafarullah, Leonard Abbeduto, Randi Hagerman, Andrea Schneider
Förderung
- NICHD NIH HHS
- Azrieli Foundation
- MIND Institute IDDRC
Zitieren
APA
Aishworiya, R., Chi, M. H., Zafarullah, M., Mendoza, G., Ponzini, M. D., Kim, K., Biag, H. M. B., Thurman, A. J., Abbeduto, L., Hessl, D., Randol, J. L., Bolduc, F. V., Jacquemont, S., Lippé, S., Hagerman, P., Hagerman, R., Schneider, A., & Tassone, F. (2023). Intercorrelation of Molecular Biomarkers and Clinical Phenotype Measures in Fragile X Syndrome. Cells. https://doi.org/10.3390/cells12141920
Vancouver
Aishworiya R, Chi MH, Zafarullah M, Mendoza G, Ponzini MD, Kim K, et al. Intercorrelation of Molecular Biomarkers and Clinical Phenotype Measures in Fragile X Syndrome. Cells. 2023. doi:10.3390/cells12141920
BibTeX
@article{Aishworiya2023,
author = {Aishworiya, Ramkumar and Chi, Mei-Hung and Zafarullah, Marwa and Mendoza, Guadalupe and Ponzini, Matthew Dominic and Kim, Kyoungmi and Biag, Hazel Maridith Barlahan and Thurman, Angela John and Abbeduto, Leonard and Hessl, David and Randol, Jamie Leah and Bolduc, Francois V and Jacquemont, Sebastien and Lippé, Sarah and Hagerman, Paul and Hagerman, Randi and Schneider, Andrea and Tassone, Flora},
title = {Intercorrelation of Molecular Biomarkers and Clinical Phenotype Measures in Fragile X Syndrome},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12141920}
}
EUVIMED